Is Ticagrelor the Antiplatelet Therapy Panacea?

por Beitelshees, Amber L.
Publicado em 2010

Renin–angiotensin–aldosterone system (RAAS) pharmacogenomics: implications in heart failure management

por Beitelshees, Amber L., Zineh, Issam
Publicado no Heart Fail Rev (2008)

Evolving research and stakeholder perspectives on pharmacogenomics

por Beitelshees, Amber L., Veenstra, David L.
Publicado em 2011

Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics

por Beitelshees, Amber L, Voora, Deepak, Lewis, Joshua P
Publicado no Pharmgenomics Pers Med (2015)

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research

por Beitelshees, Amber L., Leslie, Bruce R., Taylor, Simeon I.
Publicado no Diabetes (2019)

Pharmacological treatment of hyperglycemia in type 2 diabetes

por Taylor, Simeon I., Yazdi, Zhinous Shahidzadeh, Beitelshees, Amber L.
Publicado no J Clin Invest (2021)

Cost-Effectiveness of Cytochrome P450 2C19 Genotype Screening for Selection of Antiplatelet Therapy with Clopidogrel or Prasugrel

por Reese, Emily S., Mullins, C. Daniel, Beitelshees, Amber L., Onukwugha, Eberechukwu
Publicado em 2012

Serum Monocyte Chemoattractant Protein-1 Concentrations Associate With Diabetes Status but Not Arterial Stiffness in Children With Type 1 Diabetes

por Zineh, Issam, Beitelshees, Amber L., Silverstein, Janet H., Haller, Michael J.
Publicado em 2009

SGLT2 Inhibitors as Adjunctive Therapy for Type 1 Diabetes: Balancing Benefits versus Risks

por Taylor, Simeon I., Blau, Jenny E., Rother, Kristina I., Beitelshees, Amber L.
Publicado no Lancet Diabetes Endocrinol (2019)

Single nucleotide polymorphism discovery and haplotype analysis of Ca(2+)-dependent K(+) channel beta-1 subunit

por Gong, Yan, Beitelshees, Amber L., Wessel, Jennifer, Langaee, Taimour Y., Schork, Nicholas J., Johnson, Julie A.
Publicado em 2007

CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults

por Beitelshees, Amber L, Aquilante, Christina L, Allayee, Hooman, Langaee, Taimour Y, Welder, Gregory J, Schofield, Richard S, Zineh, Issam
Publicado em 2012

Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project

por Cutting, Elizabeth M., Overby, Casey L., Banchero, Meghan, Pollin, Toni, Kelemen, Mark, Shuldiner, Alan R., Beitelshees, Amber L.
Publicado no AMIA Annu Symp Proc (2015)

Epithelial Neutrophil-Activating Peptide (ENA-78), Acute Coronary Syndrome Prognosis, and Modulatory Effect of Statins

por Zineh, Issam, Beitelshees, Amber L., Welder, Gregory J., Hou, Wei, Chegini, Nasser, Wu, Jun, Cresci, Sharon, Province, Michael A., Spertus, John A.
Publicado em 2008

Comparison of Office, Ambulatory, and Home Blood Pressure Antihypertensive Response to Atenolol and Hydrochlorthiazide

por Beitelshees, Amber L., Gong, Yan, Bailey, Kent R., Turner, Stephen T., Chapman, Arlene B., Schwartz, Gary L., Gums, John G., Boerwinkle, Eric, Johnson, Julie A.
Publicado em 2009

Adrenergic-pathway Gene Variants Influence β-Blocker-related Outcomes after Acute Coronary Syndrome in a Race-specific Manner

por Cresci, Sharon, Dorn, Gerald W., Jones, Philip G., Beitelshees, Amber L., Li, Allie Y., Lenzini, Petra A., Province, Michael A., Spertus, John A., Lanfear, David E.
Publicado em 2012

A PPARα Promoter Variant Impairs ERR-Dependent Transactivation and Decreases Mortality after Acute Coronary Ischemia in Patients with Diabetes

por Cresci, Sharon, Huss, Janice M., Beitelshees, Amber L., Jones, Philip G., Minton, Matt R., Dorn, Gerald W., Kelly, Daniel P., Spertus, John A., McLeod, Howard L.
Publicado em 2010

Plasma Renin Activity Predicts Blood Pressure Responses to β-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension

por Turner, Stephen T., Schwartz, Gary L., Chapman, Arlene B., Beitelshees, Amber L., Gums, John G., Cooper-DeHoff, Rhonda M., Boerwinkle, Eric, Johnson, Julie A., Bailey, Kent R.
Publicado em 2010

Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response

por Turner, Stephen T, Schwartz, Gary L, Chapman, Arlene B, Beitelshees, Amber L, Gums, John G, Cooper-DeHoff, Rhonda M, Boerwinkle, Eric, Johnson, Julie A, Bailey, Kent R
Publicado em 2012

Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide

por Del-Aguila, Jorge L., Cooper-DeHoff, Rhonda M., Chapman, Arlene B., Gums, John G., Beitelshees, Amber L., Bailey, Kent, Turner, Stephen T., Johnson, Julie A., Boerwinkle, Eric
Publicado no Pharmacogenomics J (2014)

Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol

por Smith, Steven M., Gong, Yan, Turner, Stephen T., Cooper-DeHoff, Rhonda M., Beitelshees, Amber L., Chapman, Arlene B., Boerwinkle, Eric, Bailey, Kent, Johnson, Julie A., Gums, John G.
Publicado em 2011